A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain

Author： Katz Nathaniel   Rauck Richard   Ahdieh Harry   Ma Tina   Gerritsen van der Hoop Roland   Kerwin Rosemary   Podolsky Gilbert  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.23, Iss.1, 2007-01, pp. : 117-128

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study

By Portenoy Russell K.   Messina John   Xie Fang   Peppin John  

Current Medical Research and Opinion, Vol. 23, Iss. 1, 2007-01 ,pp. : 223-233

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double‐blind placebo‐controlled 102‐week trial

By  

DIABETIC MEDICINE, Vol. 32, Iss. 4, 2015-04 ,pp. : 531-541

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy of the NMDA-receptor antagonist memantine in patients with chronic phantom limb pain - results of a randomized double-blinded, placebo-controlled trial

By Maier C.   Dertwinkel R.   Mansourian N.   Hosbach I.   Schwenkreis P.   Senne I.   Skipka G.   Zenz M.   Tegenthoff M.  

Pain, Vol. 103, Iss. 3, 2003-06 ,pp. : 277-283

Elsevier

Access to resources Recommend Favorite

Low doses of transdermal fentanyl in opioid-naive patients with cancer pain

By Mercadante Sebastiano   Porzio Gianpiero   Ferrera Patrizia   Aielli Federica   Adile Claudio   Ficorella Corrado  

Current Medical Research and Opinion, Vol. 26, Iss. 12, 2010-12 ,pp. : 2765-2768

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16‐week, randomized, placebo‐controlled trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 7, 2015-07 ,pp. : 699-702

John Wiley & Sons Inc

Access to resources Recommend Favorite